- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Congo Red.
Displaying page 1 of 2.
EudraCT Number: 2010-022313-25 | Sponsor Protocol Number: CL-503012 | Start Date*: 2011-01-17 | |||||||||||
Sponsor Name:A.T. Development Switzerland SARL | |||||||||||||
Full Title: International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA™ in Preventing Renal Function Decline in Patients With AA Amyloidosis | |||||||||||||
Medical condition: Renal Function Decline in Patients With AA Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SE (Completed) GB (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) BG (Completed) PT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007125-39 | Sponsor Protocol Number: LeBenD | Start Date*: 2011-04-19 |
Sponsor Name:Klinik f. Innere Med., Fachabteilung Hämatologie | ||
Full Title: A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation | ||
Medical condition: AL-amyloidose | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-005384-16 | Sponsor Protocol Number: FLORAMICAR | Start Date*: 2016-04-26 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl... | ||||||||||||||||||
Medical condition: Patients with high clinical suspicion of cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005287-27 | Sponsor Protocol Number: Doxycycline in ATTR | Start Date*: 2007-10-15 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline on disease progression in early to moderate ATTR amyloidosis | |||||||||||||
Medical condition: ATTR amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005236-25 | Sponsor Protocol Number: Dox/Urso | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Umeå University | |||||||||||||
Full Title: A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis | |||||||||||||
Medical condition: Transthyretin amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000489-50 | Sponsor Protocol Number: AC-009-IT | Start Date*: 2017-10-03 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: A Phase II, Single Arm, Open Label, Efficacy and Safety Study of NEOD001 in Subjects with Light Chain (AL) Amyloidosis with Hepatic Involvement | |||||||||||||
Medical condition: AL amyloidosis with hepatic involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001737-27 | Sponsor Protocol Number: 54767414AMY3001 | Start Date*: 2018-04-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos... | |||||||||||||
Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) SE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003835-20 | Sponsor Protocol Number: ALN-TTRSC-004 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyl... | |||||||||||||
Medical condition: Transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000276-23 | Sponsor Protocol Number: 201464 | Start Date*: 2016-12-06 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis | ||||||||||||||||||
Medical condition: Systemic amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000713-32 | Sponsor Protocol Number: CAEL101-302 | Start Date*: 2020-12-23 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIa cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Completed) AT (Ongoing) CZ (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003865-11 | Sponsor Protocol Number: NEOD001-CL002 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai... | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000012-24 | Sponsor Protocol Number: DOXATTR | Start Date*: 2006-01-24 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A phase II study of the safety and efficacy of doxycycline administered cyclically in patients suffering from Transthyretin Amiloidosis ATTR | |||||||||||||
Medical condition: Transthyretin amyloidosis ATTR | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006395-37 | Sponsor Protocol Number: BRD/06/055 | Start Date*: 2007-09-06 | |||||||||||
Sponsor Name:Joint UCLH and UCL Biomedical Research Unit | |||||||||||||
Full Title: A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would no... | |||||||||||||
Medical condition: The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002761-19 | Sponsor Protocol Number: OP201 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy | |||||||||||||
Medical condition: Patients with AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001458-24 | Sponsor Protocol Number: ALN-TTR02-011 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) DK (Ongoing) BG (Completed) PT (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002835-27 | Sponsor Protocol Number: ION-682884-CS2 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | |||||||||||||
Medical condition: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) PT (Ongoing) AT (Ongoing) DK (Ongoing) BE (Ongoing) GR (Ongoing) CZ (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004318-14 | Sponsor Protocol Number: NEOD001-201 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004254-28 | Sponsor Protocol Number: CAEL101-301 | Start Date*: 2021-01-07 | |||||||||||
Sponsor Name:Caelum Biosciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIb cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) BE (Trial now transitioned) AT (Ongoing) CZ (Trial now transitioned) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005468-10 | Sponsor Protocol Number: C16011 | Start Date*: 2012-11-28 |
Sponsor Name:Millennium Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refra... | ||
Medical condition: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) GB (Prematurely Ended) IT (Ongoing) GR (Completed) ES (Prematurely Ended) DK (Completed) CZ (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.